Boston Scientific (NYSE:BSX) Sets New 12-Month Low – Here’s What Happened

Boston Scientific Corporation (NYSE:BSX) hit a new 52-week low during mid-day trading on Thursday. The company traded as low as $41.50 and last traded at $41.5470, with a volume of 15,871,082 shares changing hands. The stock had previously closed at $42.19.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific sued Johnson & Johnson over alleged patent infringement involving a tool used in heart procedures. Although the litigation creates uncertainty, a successful outcome could help protect Boston Scientific’s intellectual property and competitive position. Boston Scientific sues J&J for patent infringement over heart procedure tool
• Neutral Sentiment: The company appointed Joseph Fitzgerald as chief operating officer and is reorganizing into three operating segments. The changes could improve accountability and execution, but investors may initially view the restructuring as an indication that management is seeking to streamline operations. Boston Scientific Names Joseph Fitzgerald as COO Why Is Boston Scientific Reorganizing Into Three Segments Under A New COO?
• Neutral Sentiment: Barclays initiated coverage with an Equal Weight rating, also described in related coverage as a Hold. The stance suggests the firm sees limited near-term outperformance potential rather than a strong bullish or bearish catalyst. Barclays initiates coverage of Boston Scientific with equal-weight
• Negative Sentiment: BSX reached a new 52-week low near $41.50 amid elevated trading volume. The stock remains substantially below its 50-day average of $46.64 and 200-day average of $50.71, signaling weak momentum and continued investor caution. Boston Scientific Reaches New 1-Year Low

Wall Street Analyst Weigh In

BSX has been the topic of several analyst reports. Jefferies Financial Group dropped their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Truist Financial decreased their target price on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Royal Bank Of Canada decreased their price objective on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. Robert W. Baird set a $56.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Finally, BTIG Research reduced their target price on Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a research note on Wednesday, September 9th. Twenty-two analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $66.31.

Boston Scientific Stock Performance

The firm has a market capitalization of $61.90 billion, a P/E ratio of 17.29, a P/E/G ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The firm has a 50-day moving average price of $46.56 and a two-hundred day moving average price of $50.65.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts forecast that Boston Scientific Corporation will post 3.25 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael Mahoney purchased 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward Ludwig acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The shares were acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 194,522 shares of company stock worth $9,385,210 in the last three months. 0.34% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BSX. Perigon Wealth Management LLC bought a new position in Boston Scientific in the 2nd quarter valued at $883,000. Y Intercept Hong Kong Ltd raised its stake in Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after purchasing an additional 670,060 shares in the last quarter. Wealthfront Advisers LLC acquired a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab raised its stake in Boston Scientific by 9.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after acquiring an additional 28,961 shares in the last quarter. Finally, Tocqueville Asset Management L.P. bought a new stake in Boston Scientific during the 2nd quarter worth approximately $38,539,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.